BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 3422208)

  • 1. Combination assay of CA125, TPA, IAP, CEA, and ferritin in serum for ovarian cancer.
    Yabushita H; Masuda T; Ogawa A; Noguchi M; Ishihara M
    Gynecol Oncol; 1988 Jan; 29(1):66-75. PubMed ID: 3422208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms].
    Yabushita H; Masuda T; Hattori A; Noguchi M; Ito Y; Nakanishi M; Ishihara M
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of six tumor markers in patients with benign and malignant gynecological disease.
    Fukazawa I; Inaba N; Ota Y; Sato N; Shirotake S; Iwasawa H; Sato T; Takamizawa H; Wiklund B
    Arch Gynecol Obstet; 1988; 243(2):61-8. PubMed ID: 3401042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.
    Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers].
    Suzumori K; Yasui Y; Asai H; Hisaoka T; Mizuno K; Yagami Y
    Gan No Rinsho; 1985 May; 31(5):544-8. PubMed ID: 3860666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
    Fukazawa I; Inaba N; Ota Y; Sato N; Shirotake S; Iwasawa H; Sekiya S; Takamizawa H; Suzuki N; Tokita H
    Arch Gynecol Obstet; 1988; 243(2):69-81. PubMed ID: 3165255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
    Kataoka A; Yakushiji M
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma.
    Panza N; Pacilio G; Campanella L; Peluso G; Battista C; Amoriello A; Utech W; Vacca C; Lombardi G
    Cancer; 1988 Jan; 61(1):76-83. PubMed ID: 2446734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnostic value of serological tumor marker tests in patients with ovarian cancer].
    Kobayashi H; Sumimoto K; Terao T; Kawashima Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Oct; 41(10):1501-6. PubMed ID: 2573640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of statistical discrimination employing serum TA-4, TPA, and CEA levels in uterine cervical cancer.
    Yabushita H; Ogawa A; Masuda T; Noguchi M; Nakanishi M; Ishihara M
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Oct; 38(10):1770-6. PubMed ID: 3782958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
    Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
    Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serodiagnostic tests by factor analysis and stepwise discriminating analysis with tumor markers for the detection of ovarian cancer].
    Kobayashi H; Sumimoto K; Terao T; Kawashima Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1903-10. PubMed ID: 2480396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of tumor markers and their clinical significance in epithelial ovarian cancer.
    Shan D; Cheng S; Ma Y; Peng H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jul; 48(7):1039-1049. PubMed ID: 37724407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Predictive value of a tumor marker combination for the monitoring of ovarian cancer].
    Lahousen M
    Wien Klin Wochenschr; 1986 May; 98(10):319-25. PubMed ID: 3460273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical significance of serum tumor markers (CEA, TPA, IAP and ferritin) in pulmonary tuberculosis].
    Komatsu H
    Kekkaku; 1987 Jan; 62(1):31-6. PubMed ID: 3573509
    [No Abstract]   [Full Text] [Related]  

  • 16. [Significance of tumor markers in the treatment of patients with ovarian malignancies].
    Tomoda Y; Kano T; Furuhashi Y; Mizuno K; Kamiya N; Mizuno K; Sakakibara K; Ohta M
    Gan To Kagaku Ryoho; 1987 Nov; 14(11):3027-33. PubMed ID: 2445293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical usefulness of serum TPA, IAP and CEA levels in gynecological cancer].
    Saitoh S; Nakanishi A; Noda T; Ando Y; Kamamoto Y; Moriyama I; Ichijo M
    Nihon Gan Chiryo Gakkai Shi; 1984 Aug; 19(7):1496-504. PubMed ID: 6520506
    [No Abstract]   [Full Text] [Related]  

  • 18. [Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers].
    Kawai M; Yamashita H; Hayashi T; Kamiya N; Kakihara M; Arii Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Mar; 38(3):402-10. PubMed ID: 3457877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation between serum levels of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) and their immunohistochemical identification in benign and malignant gynecological disease.
    Fukazawa I; Inaba N; Ota Y; Sato N; Shirotake S; Iwasawa H; Sato T; Takamizawa H; Wiklund B
    Arch Gynecol Obstet; 1988; 243(1):41-50. PubMed ID: 3165614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Field trial for the early detection of patients with ovarian cancer--discrimination of ovarian cancer patients by the statistical analysis using Mahalanobis' generalized distance].
    Kobayashi H; Sumimoto K; Terao T; Kawashima Y; Okada K
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Feb; 44(2):174-80. PubMed ID: 1372032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.